Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million Acquisition of Stemline establishes Menarini’s presence in the U.S. biopharmaceutical oncology market Menarini will support further development of Stemline’s ELZONRIS® and enable global expansion by leveraging its commercial infrastructure in Europe and other ex-U.S. geographies Total potential consideration of $12.50 per share comprising $11.50 cash and $1.00 Contingent Value Right (CVR) FLORENCE, Italy and NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Menarini Group, a privately held Italian phar...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.